$BMRN
BIOMARIN PHARMACEUTICAL INC

2020 Q4 Form 10-Q Financial Statement

#000104847720000029 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $452.1M $476.8M $461.1M
YoY Change -0.51% 3.4% 17.72%
Cost Of Revenue $126.1M $188.8M $96.95M
YoY Change 31.49% 94.73% 22.89%
Gross Profit $326.0M $288.0M $364.1M
YoY Change -9.07% -20.91% 16.41%
Gross Profit Margin 72.11% 60.4% 78.97%
Selling, General & Admin $186.0M $179.5M $170.1M
YoY Change -0.96% 5.49% 14.5%
% of Gross Profit 57.06% 62.31% 46.72%
Research & Development $156.7M $147.1M $173.0M
YoY Change -9.32% -14.98% 7.16%
% of Gross Profit 48.07% 51.06% 47.5%
Depreciation & Amortization $27.40M $11.10M $24.24M
YoY Change 6.2% -54.2% -8.88%
% of Gross Profit 8.4% 3.85% 6.66%
Operating Expenses $358.4M $326.5M $343.1M
YoY Change -4.91% -4.83% 10.68%
Operating Profit -$32.40M -$55.94M $4.010M
YoY Change 76.09% -1495.04% -125.47%
Interest Expense -$13.10M $9.597M $2.937M
YoY Change 469.57% 226.76% -75.79%
% of Operating Profit 73.24%
Other Income/Expense, Net $5.300M $1.200M $4.000M
YoY Change 488.89% -70.0% 53.85%
Pretax Income -$40.20M -$61.22M $9.822M
YoY Change 310.2% -723.25% -150.59%
Income Tax -$600.0K -$846.0M -$45.21M
% Of Pretax Income -460.33%
Net Earnings $22.10M $784.8M $55.04M
YoY Change 47.33% 1325.98% -536.1%
Net Earnings / Revenue 4.89% 164.6% 11.94%
Basic Earnings Per Share $4.33 $0.31
Diluted Earnings Per Share $121.6K $4.01 $0.30
COMMON SHARES
Basic Shares Outstanding 181.5M shares 181.1M shares 179.3M shares
Diluted Shares Outstanding 197.7M shares 185.9M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.065B $1.506B $720.8M
YoY Change 41.33% 108.89% -50.06%
Cash & Equivalents $649.2M $1.016B $423.2M
Short-Term Investments $416.2M $490.0M $297.6M
Other Short-Term Assets $129.9M $120.7M $126.5M
YoY Change -0.55% -4.58% 76.5%
Inventory $698.5M $700.8M $609.0M
Prepaid Expenses
Receivables $448.4M $411.7M $403.0M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.342B $2.739B $1.859B
YoY Change 20.6% 47.31% -22.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.032B $1.015B $969.3M
YoY Change 2.14% 4.72% 4.9%
Goodwill $196.2M $196.2M $197.0M
YoY Change -0.43% -0.43%
Intangibles $417.3M $427.2M $462.8M
YoY Change -8.61% -7.71%
Long-Term Investments $285.5M $265.1M $431.8M
YoY Change -30.7% -38.61% 110.74%
Other Assets $142.2M $119.0M $112.6M
YoY Change 16.58% 5.65% -75.87%
Total Long-Term Assets $3.506B $3.419B $2.699B
YoY Change 27.58% 26.69% 17.98%
TOTAL ASSETS
Total Short-Term Assets $2.342B $2.739B $1.859B
Total Long-Term Assets $3.506B $3.419B $2.699B
Total Assets $5.848B $6.158B $4.558B
YoY Change 24.69% 35.1% -2.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $191.4M $218.0M $233.5M
YoY Change -20.58% -6.64% 29.29%
Accrued Expenses $266.3M $231.7M $223.2M
YoY Change -7.5% 3.81% 26.75%
Deferred Revenue $152.0K $10.93M
YoY Change -98.83%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.900M $377.4M $3.000M
YoY Change -99.21% 12480.0% -99.2%
Total Short-Term Liabilities $492.5M $854.7M $493.7M
YoY Change -47.18% 73.1% -41.13%
LONG-TERM LIABILITIES
Long-Term Debt $1.079B $1.079B $853.2M
YoY Change 118.95% 26.43% 3.28%
Other Long-Term Liabilities $114.2M $121.2M $97.43M
YoY Change 16.38% 24.43% -15.64%
Total Long-Term Liabilities $114.2M $121.2M $97.43M
YoY Change 16.38% 24.43% -89.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $492.5M $854.7M $493.7M
Total Long-Term Liabilities $114.2M $121.2M $97.43M
Total Liabilities $1.742B $2.104B $1.484B
YoY Change 11.12% 41.82% -16.66%
SHAREHOLDERS EQUITY
Retained Earnings -$861.6M -$883.7M -$1.736B
YoY Change -49.93% -49.09%
Common Stock $4.994B $4.938B $4.783B
YoY Change 3.33% 3.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.106B $4.054B $3.074B
YoY Change
Total Liabilities & Shareholders Equity $5.848B $6.158B $4.558B
YoY Change 24.69% 35.1% -2.92%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $22.10M $784.8M $55.04M
YoY Change 47.33% 1325.98% -536.1%
Depreciation, Depletion And Amortization $27.40M $11.10M $24.24M
YoY Change 6.2% -54.2% -8.88%
Cash From Operating Activities -$13.30M $86.20M $70.10M
YoY Change -123.17% 22.97% 48.52%
INVESTING ACTIVITIES
Capital Expenditures -$39.80M -$20.20M -$35.40M
YoY Change -34.54% -42.94% -28.92%
Acquisitions
YoY Change
Other Investing Activities $50.90M $126.8M $84.10M
YoY Change 324.17% 50.77% -81.4%
Cash From Investing Activities $11.00M $106.7M $48.70M
YoY Change -122.49% 119.1% -87.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -366.2M 3.300M -2.000M
YoY Change -9255.0% -265.0% -138.46%
NET CHANGE
Cash From Operating Activities -13.30M 86.20M 70.10M
Cash From Investing Activities 11.00M 106.7M 48.70M
Cash From Financing Activities -366.2M 3.300M -2.000M
Net Change In Cash -368.5M 196.2M 116.8M
YoY Change -3048.0% 67.98% -74.31%
FREE CASH FLOW
Cash From Operating Activities -$13.30M $86.20M $70.10M
Capital Expenditures -$39.80M -$20.20M -$35.40M
Free Cash Flow $26.50M $106.4M $105.5M
YoY Change -77.58% 0.85% 8.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
CY2020Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-26727
dei Entity Registrant Name
EntityRegistrantName
BioMarin Pharmaceutical Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
506-6700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
BMRN
dei Trading Symbol
TradingSymbol
BMRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
181529667 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1015675000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
437446000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
489998000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
316361000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
411712000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
377404000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
700847000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
680275000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
120747000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
130657000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
2738979000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1942143000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
265122000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
411978000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
549422000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
119009000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122009000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1015062000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1010868000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
427172000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
456580000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
196199000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
197039000 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1396547000 USD
CY2020Q3 us-gaap Assets
Assets
6158090000 USD
CY2019Q4 us-gaap Assets
Assets
4690039000 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
480403000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
570621000 USD
CY2020Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
374290000 USD
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
361882000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98124000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
854693000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
932503000 USD
CY2020Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1074164000 USD
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
486238000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
54103000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
50793000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
121237000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
2104197000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
1567658000 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
181492344 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
181492344 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
179838114 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
179838114 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
181000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
180000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4937791000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4832707000 USD
CY2020Q3 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
10756000 USD
CY2019Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9961000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10385000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
20164000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-883708000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1720709000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
4053893000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3122381000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6158090000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4690039000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1249605000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1408338000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
476784000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
461097000 USD
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
188793000 USD
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
96949000 USD
us-gaap Cost Of Revenue
CostOfRevenue
398134000 USD
us-gaap Cost Of Revenue
CostOfRevenue
263567000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147053000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172963000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
471449000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
542195000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
179450000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
170112000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
542157000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
493024000 USD
CY2020Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17429000 USD
CY2019Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17063000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
48018000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
57114000 USD
CY2020Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2019Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
59495000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
15000000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
532725000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
457087000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1400263000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1340900000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55941000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
4010000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8075000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-91295000 USD
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-921000 USD
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-551000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1077000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-780000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4004000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5340000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
13539000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17537000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
9597000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
2937000 USD
us-gaap Interest Expense
InterestExpense
24560000 USD
us-gaap Interest Expense
InterestExpense
16530000 USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1239000 USD
CY2019Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3960000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1886000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
6038000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61216000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9822000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2137000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-85030000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-846019000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
3074405000 USD
us-gaap Net Income Loss
NetIncomeLoss
837001000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180592000 shares
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45214000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-839138000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-46158000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
784803000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
55036000 USD
us-gaap Net Income Loss
NetIncomeLoss
837001000 USD
us-gaap Net Income Loss
NetIncomeLoss
-38872000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.33
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.01
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181142000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179289000 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
827222000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178873000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197674000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185924000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194959000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178873000 shares
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
765138000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
74600000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7140000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3236679000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2960954000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3122381000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2967940000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
4053893000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
3074405000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
4053893000 USD
us-gaap Net Income Loss
NetIncomeLoss
-38872000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77814000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79510000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
14766000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9395000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-175000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1897000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
142125000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
121763000 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
59495000 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
15000000 USD
us-gaap Inventory Write Down
InventoryWriteDown
75609000 USD
us-gaap Inventory Write Down
InventoryWriteDown
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-854199000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-59780000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-9082000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-784000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1352000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5646000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-388000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
18000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32915000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
61803000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
73310000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
52571000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-32848000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
13259000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5543000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7112000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-76174000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21747000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
9225000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2386000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
98749000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9081000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83286000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94241000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
345224000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
635678000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
369942000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
528497000 USD
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
67159000 USD
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
15000000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14369000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8323000 USD
bmrn Payments To Acquire Debt Securities Available For Sale Non Marketable
PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
8709000 USD
bmrn Payments To Acquire Debt Securities Available For Sale Non Marketable
PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
725000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1747000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64648000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17870000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
60268000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21768000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
42667000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
40951000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
57508000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
585752000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-6080000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2025000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
547273000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-78716000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3145000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-835000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
578229000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70762000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
437446000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
493982000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1015675000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
423220000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
4355000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
6088000 USD
us-gaap Interest Paid Net
InterestPaidNet
5615000 USD
us-gaap Interest Paid Net
InterestPaidNet
5777000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-13281000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-5801000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
-3043000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
2053000 USD
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF OPERATIONS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div>
us-gaap Basis Of Accounting
BasisOfAccounting
BASIS OF PRESENTATION<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that, except for the maturity and settlement of our convertible debt discussed in Note 12 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1763780000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7030000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1770795000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1015675000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
489998000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
411978000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
265122000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1161152000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4713000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
80000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1165785000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
437446000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
316361000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
638468000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
652734000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
211296000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
196154000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
427172000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
456580000 USD
CY2019Q2 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
15000000.0 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1628745000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1559968000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
613683000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
549100000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1015062000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1010868000 USD
CY2020Q3 us-gaap Depreciation
Depreciation
22187000 USD
CY2019Q3 us-gaap Depreciation
Depreciation
24238000 USD
us-gaap Depreciation
Depreciation
65749000 USD
us-gaap Depreciation
Depreciation
67206000 USD
CY2020Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
10883000 USD
CY2019Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
9807000 USD
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
34053000 USD
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
24894000 USD
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
73857000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
74442000 USD
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
296685000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
349978000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
330305000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
255855000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
700847000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
680275000 USD
CY2020Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
218021000 USD
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
240981000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
137415000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
192467000 USD
CY2020Q3 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
65999000 USD
CY2019Q4 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
57163000 USD
CY2020Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
20426000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
30797000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10930000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10700000 USD
CY2020Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
7222000 USD
CY2019Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
8395000 USD
CY2020Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7774000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10448000 USD
CY2020Q3 bmrn Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
3240000 USD
CY2019Q4 bmrn Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
13037000 USD
CY2020Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
9376000 USD
CY2020Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
18174000 USD
CY2019Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
33592000 USD
CY2020Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
12180000 USD
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6633000 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
480403000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
570621000 USD
CY2019Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
15941000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
532725000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
457087000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1400263000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1340900000 USD
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
4800000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45764000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49045000 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
12018000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
10389000 USD
CY2020Q3 bmrn Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
57782000 USD
CY2019Q4 bmrn Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
59434000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7813000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7451000 USD
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3117000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3249000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40831000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44092000 USD
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4570000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
6708000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
56331000 USD
CY2019Q4 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
61500000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3460000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
940000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
48000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Remainder Of Fiscal Year
OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
4400000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9908000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3080000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Due Year One
OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne
12988000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9095000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
2375000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Due Year Two
OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
11470000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8055000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
1797000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Due Year Three
OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
9852000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6253000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Due Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour
6301000 USD
CY2020Q3 bmrn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
21714000 USD
CY2020Q3 bmrn Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
20000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Due After Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour
21734000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
58485000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
8260000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Payments Due
OperatingAndFinanceLeaseLiabilityPaymentsDue
66745000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9841000 USD
CY2020Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
573000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability Undiscounted Excess Amount
OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
10414000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
48644000 USD
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
7687000 USD
CY2020Q3 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
56331000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
4179000 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
4277000 USD
us-gaap Lease Cost
LeaseCost
11612000 USD
us-gaap Lease Cost
LeaseCost
12212000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2020Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2019Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.051
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.052
CY2019Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.054
CY2020Q3 bmrn Operating Leases Not Yet Commenced Expected To Commence By End Of Fiscal Year
OperatingLeasesNotYetCommencedExpectedToCommenceByEndOfFiscalYear
1 lease
us-gaap Operating Lease Payments
OperatingLeasePayments
7007000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5918000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
354000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
454000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6080000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2027000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3299000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9268000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
3941000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
72000 USD
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1500000000 USD
CY2020Q3 us-gaap Convertible Debt
ConvertibleDebt
1448454000 USD
CY2019Q4 us-gaap Convertible Debt
ConvertibleDebt
848120000 USD
CY2020Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1482737000 USD
CY2019Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
927518000 USD
CY2020Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
-18295000 USD
CY2020Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
1878000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-508000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-19665000 USD
CY2019Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
24492000 USD
CY2019Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
4808000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
120000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19564000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
3798000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
13027000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
550000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9779000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
42684000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
9286000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
1666000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
31732000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
476784000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
461097000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1408338000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1249605000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50169000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39173000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
142125000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121763000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
4900000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
14900000 USD
CY2019Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5100000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
13200000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
784803000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
55036000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
837001000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38872000 USD
CY2020Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
7070000 USD
CY2019Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
937000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
18333000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
791873000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
55973000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
855334000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38872000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181142000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179289000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180592000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178873000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197674000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185924000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194959000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178873000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.33
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.01
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8265000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13394000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8439000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20028000 shares
bmrn Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
622400000 USD
CY2020Q3 bmrn Contingent Liability Accrual Sales And Licensing Milestones
ContingentLiabilityAccrualSalesAndLicensingMilestones
54100000 USD

Files In Submission

Name View Source Status
0001048477-20-000029-index-headers.html Edgar Link pending
0001048477-20-000029-index.html Edgar Link pending
0001048477-20-000029.txt Edgar Link pending
0001048477-20-000029-xbrl.zip Edgar Link pending
bmrn-20200930.htm Edgar Link pending
bmrn-20200930.xsd Edgar Link pending
bmrn-20200930_cal.xml Edgar Link unprocessable
bmrn-20200930_def.xml Edgar Link unprocessable
bmrn-20200930_htm.xml Edgar Link completed
bmrn-20200930_lab.xml Edgar Link unprocessable
bmrn-20200930_pre.xml Edgar Link unprocessable
exhibit311-30sep20x10q.htm Edgar Link pending
exhibit312-30sep20x10q.htm Edgar Link pending
exhibit321-30sep20x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending